No abstract

IntroductionPatients with glioma (GM) are at a high risk of venous thromboembolism (VTE). The role of microvesiculation in the cancer-associated thrombosis mechanisms has been previously demonstrated. This study aimed to evaluate the relative abundance of extracellular vesicles (EVs) and thrombin generation (TG) in combination with standard laboratory tests in patients with newly diagnosed GM as potential prognostic markers in VTE.Materials and MethodsIn the present study, 11 patients with newly diagnosed GM and 10 healthy volunteers were analyzed. EVs were counted and their cellular origin was determined (CytoFlex B4-R2-V2, Beckman Coulter, United States), as well as thrombin generation test (TGT) (Diagnostica Stago SAS, France) was performed.ResultsIn patients with GM, the relative abundance of the CD41 + EVs (platelet-derived)—and CD105 + EVs (endothelial-derived) was significantly higher than in the control group (44.3 [40.5; 52.4] vs. 27.2 [22.9; 31.0]%, p = 0.002, and 5.4 [4.8; 7.8] vs. 1.9 [1.5; 2.8]%, p = 0.0003, respectively). The D-dimer level was higher in patients with GM compared with the control group (0.46 [0.38; 1.85] vs. 0.36 [0.27; 0.40] μg/ml FEU, p = 0.03, respectively). There was a trend toward an increase in the peak thrombin and velocity index (VI) in the GM group (p = 0.06). During the follow-up period, two patients (18%) developed thrombosis, had tumor sizes of more than 5 cm, thrombocytopenia, increased VI, and D-dimer.ConclusionAnalysis of platelet-derived EVs, platelet count, and TGT in combination with D-dimer assessment could improve the stratification of patients prone to VTE, which needs to be confirmed in a larger sample.

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Научный центр мирового уровня «Центр персонализированной медицины»,

Diagnosis of pulmonary embolism (PE), chronic thromboembolic pulmonary hypertension (CTEPH) and other prothrombotic complications remains a challenge due to various clinical manifestations. In recent years, numerous studies have focused on finding reliable biomarkers to confirm pathology. It was shown that microRNAs (miRNAs) regulate gene expression in a wide range of pathophysiological processes, and their profile can change in different cardiovascular diseases. miRNAs are involved in many biological processes, including proliferation, apoptosis and cell differentiation, and angiogenesis. Therefore, circulating miRNAs are considered as new biomarkers. The paper presents basic information on the role of microRNA in the genesis of PE and postthromboembolic complications.

Background. The thrombin generation test (TGT) as an integral method for analyzing the activation cascade of natural pro- and anticoagulants is of practical importance in assessing the risk of thrombotic conditions and bleeding, however its application is limited by the lack of standardization. Objective. To define reference intervals within the laboratory and assess inter-individual variation in TGT values for different technologies. Design and methods. The study included 20 donors. TGT was performed using two technologies: a calibrated automated thrombogram on a semi-automatic fluorometer (Technology 1) and automatic measurement of GT on a coagulometer (Technology 2). Obtained results were normalized to pooled normal plasma. Results. Thrombogram parameters showed a high CVG (coefficient of interindividual variation): 14–32 % for Technology 1 and 7–36 % for Technology 2. CVG did not change significantly after normalization. Significant differences in ETP (endogenous thrombin potential) were noted. The reference intervals for Technology 1 were: ETR 1478.0–2595.0 nmol/ min and peak thrombin concentration (Peak thr.) 221.6–412.0 nmol. RI for Technology 2: ETP 2451.00–3161.00 nmol/min and Peak thr. 161.60–479.30 nmol. Conclusion. Comparison of the two laboratory TGT technologies revealed high inter-individual variation. Thus, the use of a study in dynamics for each specific individual is likely to be more informative than the use of RI obtained in the general population. Dynamic monitoring of the patient must be performed using one technology.